spacer
home > pmps > autumn 2017 > industry insight
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Industry Insight

Many of the manufacturing processes used for the production of medicines are pretty much the same today as they were when I began my professional career over 30 years ago. This is not necessarily due to a lack of advances in manufacturing technologies that could benefit the industry. To a large extent, the inertia for adopting alternative manufacturing technologies relates to the industry fearing rejection from the regulatory authorities for introducing such changes, which is unfounded. The value of the global pharmaceutical market is estimated to be worth over $500 billion annually, therefore improvements to manufacturing efficiencies could certainly pay dividends to companies in maximising the ‘profit’ to ‘cost of goods’ ratio.

Things are changing. The regulatory organisations are encouraging pharma manufacturers to invest in and exploit advanced manufacturing technologies, and the FDA has created the Emerging Technology Program to promote the adoption of innovative approaches to pharmaceutical product design and manufacturing (1,2).

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Robert Harris, Chief Technical Officer at Juniper Pharma Services, PMPS Industry Advisor
spacer
Robert Harris
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

PPMA Group Industry Awards 2018 Call for Entries – Deadline 31st July

The PPMA Group Industry Awards, which recognise manufacturing excellence, technical innovation, entrepreneurship as well as outstanding achievement and contribution to the industry, will this year take place at a new venue – the Hilton Birmingham Metropole Hotel at the NEC - on the 25th September 2018.
More info >>

White Papers

Biosimilars In Emerging Markets: Is It A Level Playing Field?

PRA Health Sciences (PRA)

Governments, healthcare payers, and social and health reforms, combined with the increased incidence of conditions such as cancer and diabetes are paving the way for increased uptake of biologic medicines in emerging markets. However, expensive biologic medicines can be prohibitive to many patients, creating a high level of unmet clinical need. At its best, the global expansion of biosimilars can mean a robust and steady supply of existing and new drugs reaching far-flung patient populations, but localized biosimilar drug developments, especially in China and India, combined with a lack of robust pharmacovigilance systems, threaten to derail the industry by putting patient health at risk.
More info >>

 
Industry Events

6th Annual Single Cell Analysis Congress

8-9 November 2018, London, UK

Oxford Global is proud to present its 6th Annual Single Cell Analysis Congress taking place on 8-9 November 2018 in London.  Part of the Genomics & Synthetic Biology Series UK, the congress will bring together over 600 end users representing internationally renowned research & academic institutions, clinical research institutions, healthcare organisations as well as leading pharmaceutical and biotech companies.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement